<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372954</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-Retro</org_study_id>
    <nct_id>NCT03372954</nct_id>
  </id_info>
  <brief_title>Retrograde Application of Bone Marrow Aspirate Concentrate</brief_title>
  <acronym>Retro</acronym>
  <official_title>Retrograde Application of Bone Marrow Aspirate Concentrate (BMAC) Through Coronary Sinus in Patients With Congestive Heart Failure of Ischemic Etiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our prospective randomised study is to assess the efficacy of the retrograde&#xD;
      application of non-selected bone marrow autologous cells concentrate (BMAC) in patients with&#xD;
      heart failure with reduced ejection fraction of left ventricle (HFREF) of ischemic aetiology.&#xD;
      The evaluated preparation is concentrated BMAC, obtained using Harvest SmartPReP2 technology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our assumption is that non-selected BMAC administrations will lead to improvements in the&#xD;
      left ventricular ejection fraction (LV EF), the left ventricular end-systolic and&#xD;
      end-diastolic diameters and volumes (measured with magnetic resonance imaging) compared to&#xD;
      standard heart failure therapy.&#xD;
&#xD;
      Furthermore, it will be associated with improved exercise tolerance in the six-minute&#xD;
      corridor walk test and an improvement in the life quality of patients without increasing the&#xD;
      incidence of severe ventricular arrythmias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end-systolic diameter (LVESd)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-systolic diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-systolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end-diastolic diameter (LVEDd)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-diastolic diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-diastolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ejection fraction of left ventricle (EF LV)</measure>
    <time_frame>12 month</time_frame>
    <description>ejection fraction of left ventricle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>corridor walk test</measure>
    <time_frame>12 month</time_frame>
    <description>walk distance in 6 min corridor walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>12 month</time_frame>
    <description>Quality of patients´ life using the Minnesota questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Bone marrow autologous cells concentrate (BMAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>retrograde administration on non-selected BMAC via coronary sinus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard treatment o heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMAC</intervention_name>
    <description>retrograde administration on non-selected BMAC via coronary sinus</description>
    <arm_group_label>Bone marrow autologous cells concentrate (BMAC)</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic heart failure and left ventricular ejection fraction ≤ 40% with&#xD;
             coronary artery disease and with symptoms of heart failure in the NYHA class ≥ 3 on&#xD;
             standard heart failure therapy for 3 months and in a stabilised state for at least 1&#xD;
             month&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Informed, written consent by the patient&#xD;
&#xD;
          -  Ability to comply fully with the study protocol&#xD;
&#xD;
          -  Negative pregnancy test (and effective contraception) in women with childbearing&#xD;
             potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous bone marrow disease (especially myelodysplastic syndrome or non-Hodgkin's&#xD;
             lymphoma)&#xD;
&#xD;
          -  Acute myocardial infarction ˂ 1 week&#xD;
&#xD;
          -  Active infection or antibiotics treatment ˂ 1 week&#xD;
&#xD;
          -  Previous malingant ventricular arrhythmias without cardioverter-defibrilator (ICD)&#xD;
             implantation&#xD;
&#xD;
          -  Anemia (HTC≤28%), leukocythosis (≥ 14.000/mm3) or thrombocytopenia (≤50.000/mm3)&#xD;
&#xD;
          -  Previous bleeding diathesis&#xD;
&#xD;
          -  Need for hematopoietic growth factor treatment (e.g. erythropoetin, G-CSF)&#xD;
&#xD;
          -  Impossibility of aspiration 240ml of bone marrow&#xD;
&#xD;
          -  Hepathopathy or cirrhosis (bilirubin, ALT or AST ≥ 2,5x upper limit of normal)&#xD;
&#xD;
          -  Terminal renal insufficiency or haemodyalysis&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Need for high dose (&gt; 7.5mg/day) corticotherapy within the next 6 months&#xD;
&#xD;
          -  Inability to stop anticoagulation therapy (&gt;72 hours) before bone marrow aspiration&#xD;
&#xD;
          -  Known malignancies requiring actino or chemotherapy, or previous actinotherapy&#xD;
&#xD;
          -  Patients with a BMI &gt;40&#xD;
&#xD;
          -  Known allergy to contrast agents&#xD;
&#xD;
          -  Other comorbidities with a life expectancy of 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <state>Czech Republic</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Vávra, Ass.Prof.,MD,PhD</last_name>
      <phone>0042059737</phone>
      <phone_ext>2544</phone_ext>
      <email>petr.vavra@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

